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Plasma and intracellular concentrations were assumed at steady state with a 12 
dosing interval of 12 h. The through concentration was that measured the day before drug intake 13 
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as they were no 2 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Indeed, due to the mixture of two difference 6 
assay techniques, it is not possible to define an upper limit like a “LOQ” for these data. That is 7 
why, for the estimation step, we omitted the intracellular data when they were undetectable or 8 
under the limit of quantification for one of the assay technique used. Regarding the mixture of the 9 



















































































































































































































































































































































































































































































































































































































































































































Mean metabolic ratio of 3TC (median 51.4) is much larger than the mean metabolic ratio of 5 
AZT (median 0.66). The intersubject variability of MMR was 96.8% for AZT and 32.8% for 6 
3TC, which is far lower than AZT. 3TC-TP concentrations tended to be higher than AZT-TP 7 
concentrations whereas the median mean plasma concentrations in plasma for both parent drugs 8 
are in the same range. Using descriptive statistics, Moore et al. (25) found mean 9 
intracellular/plasma concentrations ratios of 0.05% and 3%, for AZT and 3TC, respectively. If we 10 
compare the MMR of 3TC and AZT by calculating the ratio MMR AZT/MMR 3TC they are in 11 
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Fig 5.  
 
 
 
